Answer created by AI
- Like
- Disike
AI result is experimental
Generating Answer...
-
Drug Manufacturers (8860)
-
Technology (5834)
-
Therapy Area (5831)
-
Clinical Trials (4437)
-
Covid-19 (3946)
-
Supply Chain (2512)
-
Infectious Disease (1504)
-
Regulation (1443)
-
Oncology (1341)
-
deal (1176)
-
Drug Development (1153)
-
Foreign Direct Investment (1075)
-
Impact of Chinas Zero COVID lockdowns (868)
-
Covid-19 Executive Briefing (735)
-
Approvals (667)
-
Sponsored (487)
-
Treatments (428)
-
The next chapter of clinical trial services (376)
-
Cytiva Pipe dream to pipeline WP 3 (365)
-
Suvoda WP (356)
No Filter Selected
-
News Analysis and Comments (40321)
-
Press Releases (3613)
-
White Papers (1101)
-
Supplier Products (946)
-
Projects (760)
-
Suppliers (760)
-
post_tag (736)
No Filter Selected
-
Clinical IT Systems (92)
-
Contract Manufacturers (69)
-
Lab Equipment (69)
-
Supply Chain (63)
-
Clinical Trials (55)
-
Pharmaceutical & Healthcare Packaging (51)
-
Process Automation and Equipment (42)
-
Drug Delivery Systems (39)
-
Clean Rooms and Cleanroom Flooring (37)
-
API Manufacturers (27)
-
Purification and Filtration (19)
-
Commercial Packaging (18)
-
Diagnostic Imaging (18)
-
Solid Dose Manufacturing (18)
-
API Biologics (Cell, Gene, Vaccine) (17)
-
Pharmaceutical Logistics and Supply Chain (16)
-
Cloud (14)
-
Pharma Benefit (14)
-
API Chemicals (12)
-
Injectables (commercial dose) (12)
No Filter Selected
-
United States (4533)
-
Europe (1555)
-
United Kingdom (1428)
-
North America (994)
-
Global (629)
-
China (608)
-
Asia-Pacific (479)
-
Japan (334)
-
Canada (243)
-
Germany (235)
-
Switzerland (229)
-
India (222)
-
UK (156)
-
France (139)
-
Australia (130)
-
US (105)
-
Russia (100)
-
Middle East and Africa (96)
-
South Korea (92)
-
Denmark (86)
No Filter Selected
-
Bristol-Myers Squibb (375)
-
Merck (318)
-
Pfizer (282)
-
Novartis (263)
-
AstraZeneca (244)
-
F. Hoffmann-La Roche (200)
-
AbbVie (178)
-
BeiGene (148)
-
Eli Lilly and Co (148)
-
GSK (137)
-
Johnson & Johnson (132)
-
Amgen (128)
-
Gilead Sciences (111)
-
Incyte (107)
-
Boehringer Ingelheim International (103)
-
Daiichi Sankyo (91)
-
Exelixis (91)
-
Jiangsu Hengrui Medicine (89)
-
Takeda Pharmaceutical (89)
-
Sanofi (86)
No Filter Selected
-
Achondroplasia (1)
-
Acinetobacter Infections (3)
-
Acne Vulgaris (3)
-
Acquired Hemophilia A (1)
-
Acromegaly (1)
-
Acute Ischemic Stroke (6)
-
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (1)
-
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (5)
-
Acute On Chronic Liver Failure (ACLF) (1)
-
Acute Opioid Overdosage (1)
-
Acute Renal Failure (ARF) (Acute Kidney Injury) (2)
-
Acute Respiratory Distress Syndrome (1)
-
Acute Sensorineural Hearing Loss (1)
-
Acute Spinal Cord Injury (1)
-
Adenocarcinoma (1)
-
Adrenocortical Carcinoma (Adrenal Cortex Cancer) (1)
-
Adrenomyeloneuropathy (AMN) (1)
-
Alcoholic Hepatitis (2)
-
Allan-Herndon-Dudley Syndrome (Monocarboxylate Transporter-8 Deficiency) (1)
-
Allergic Asthma (2)
No Filter Selected
-
(Aceclidine + brimonidine) (1)
-
(Acetaminophen + naltrexone) (1)
-
(Acetaminophen + nefopam hydrochloride) (1)
-
(Allopurinol +verinurad) (1)
-
(Amlodipine + fimasartan potassium) (1)
-
(Amlodipine + indapamide + telmisartan) (1)
-
(Arginine + sodium succinate) (1)
-
(Atorvastatin + ezetimibe) (1)
-
(Atorvastatin + fluconazole + minocycline) (2)
-
(Avibactam + aztreonam) (8)
-
(Avibactam tomilopil + ceftibuten) (1)
-
(Azacitidine + cedazuridine) (3)
-
(Benzoyl peroxide + tretinoin) (1)
-
(Betamethasone dipropionate + calcipotriene) (1)
-
(Bezafibrate + obeticholic acid) (1)
-
(Bizalimogene ralaplasmid + Mavilimogene ralaplasmid) (1)
-
(Bizalimogene ralaplasmid + mavilimogene ralaplasmid) (1)
-
(Borneol + edaravone) (1)
-
(Brimonidine tartrate + carbachol) (1)
-
(CST-2032 + nadolol) (1)
No Filter Selected
-
Artificial Intelligence (10)
-
Big Data (4)
-
Biosimilars (5)
-
Blockchain (1)
-
Cell & Gene Therapy (13)
-
Chemotherapy (1)
-
Cloud (1)
-
Corporate Governance (3)
-
Covid-19 (5)
-
Cybersecurity (4)
-
Digitalization (2)
-
Easy & Affordable (1)
-
Electronic Medical Record (EMR) Systems (1)
-
Environmental Sustainability (6)
-
Future of Work (3)
-
Genomics (10)
-
Health & Wellness (1)
-
Immuno-oncology (19)
-
Immunotherapy (1)
No Filter Selected
Optimisation in operations: from theory to practice
Operations chiefs, logistics service providers (LSPs) and other supply chain stakeholders know that a revolution is underway in the services they provide. In theory, they could overhaul their whole supply chain; in practice, they’ll get the longest-term value from technology by letting it work for them step-by-step, as a sustainable optimiser
Amgen reports a 22% increase in Q1 2024 net revenues
Amgen announced updates in the obesity space, with topline data for MariTide expected in late 2024.
FDA grants RMAT designation to Taysha’s Rett syndrome gene therapy
The FDA has awarded the designation following a review of initial safety and efficacy data from two Phase I/II clinical trials.
Lexicon plans another bid for Zynquista in type 1 diabetes
Despite failing to get an approval for type 1 diabetes in 2019, Lexicon plans to resubmit its NDA to the FDA by mid-2024.
ESCMID 2024: Advances in drug resistance testing
Techniques such as rapid nanomotion-based susceptibility testing, and MALDI-TOF-MS could be used to identify resistance mechanisms of several deadly organisms.
Angle signs AstraZeneca deal to develop prostate cancer assay
The assay development phase is expected to complete by early 2025.
Biotechs face upward battle with recruiting patients on obesity trials
As the obesity space becomes more congested, clinical trial recruitment has become a larger issue for small biotechs.
BridgeBio Oncology Therapeutics launches with $200m funding
BBOT will advance the development of three initial cancer treatment programmes.
NHS to provide Pfizer’s Voxelotor to treat sickle cell disease
The decision will benefit up to 4,000 patients in England with the genetic blood disorder.
ImmunityBio partners with Serum Institute for BCG vaccines
The deal aims to increase the availability of sBCG for trials and accelerate the Phase II trials of iBCG in Europe.
Moderna reports $1.2bn net loss in Q1 2024
Total revenue during the quarter saw a dramatic decrease to $167m from $1.9bn in the corresponding period of 2023.
ESCMID 2024: Drug resistance in fungi – a growing issue
Emerging research from the ESCMID Global 2024 conference suggests that antifungal resistance, a global issue, is on the rise.
BIOSECURE bill targets more Chinese companies as biotechs and their customers adapt to defunding
US regulators have added more Chinese biotech companies to the list of firms posing national security risks to the US.
Cybersecurity hiring activity grew in the pharma industry in Q1 2024
The global pharmaceutical industry experienced a 29% rise in new job postings related to cybersecurity in Q1 2024 compared with…
Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1
Novo Nordisk noted a 22% boost in sales owing to increased sales of GLP-1 agonists and other obesity products.
Social prescribing: friend or foe for pharma?
As awareness surrounding social prescribing grows, can this initiative go hand in hand with the pharmaceutical industry?
Novartis acquires Mariana in $1.75bn deal to strengthen radioligand portfolio
Under the deal, Mariana will receive $1bn and up to $750m in additional milestone payments from Novartis.
Emergent cuts 300 jobs and shuts down two facilities in cost-cutting drive
The operational changes are expected to save the biotech and manufacturing organisation $80m annually.
Beyond approval: Patients pursue alternate paths to get rare disease treatments
As post-approval boundaries disproportionately affect rare disease patients, communities are rallying behind alternative options.
M&A revival with a 71% increase in billion-dollar transactions in Q1 2024
Oncology was the top therapy area for M&A deals in Q1 2024, with a total deal value of $29bn.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174
- 175
- 176
- 177
- 178
- 179
- 180
- 181
- 182
- 183
- 184
- 185
- 186
- 187
- 188
- 189
- 190
- 191
- 192
- 193
- 194
- 195
- 196
- 197
- 198
- 199
- 200
- 201
- 202
- 203
- 204
- 205
- 206
- 207
- 208
- 209
- 210
- 211
- 212
- 213
- 214
- 215
- 216
- 217
- 218
- 219
- 220
- 221
- 222
- 223
- 224
- 225
- 226
- 227
- 228
- 229
- 230
- 231
- 232
- 233
- 234
- 235
- 236
- 237
- 238
- 239
- 240
- 241
- 242
- 243
- 244
- 245
- 246
- 247
- 248
- 249
- 250
- 251
- 252
- 253
- 254
- 255
- 256
- 257
- 258
- 259
- 260
- 261
- 262
- 263
- 264
- 265
- 266
- 267
- 268
- 269
- 270
- 271
- 272
- 273
- 274
- 275
- 276
- 277
- 278
- 279
- 280
- 281
- 282
- 283
- 284
- 285
- 286
- 287
- 288
- 289
- 290
- 291
- 292
- 293
- 294
- 295
- 296
- 297
- 298
- 299
- 300
- 301
- 302
- 303
- 304
- 305
- 306
- 307
- 308
- 309
- 310
- 311
- 312
- 313
- 314
- 315
- 316
- 317
- 318
- 319
- 320
- 321
- 322
- 323
- 324
- 325
- 326
- 327
- 328
- 329
- 330
- 331
- 332
- 333
- 334
- 335
- 336
- 337
- 338
- 339
- 340
- 341
- 342
- 343
- 344
- 345
- 346
- 347
- 348
- 349
- 350
- 351
- 352
- 353
- 354
- 355
- 356
- 357
- 358
- 359
- 360
- 361
- 362
- 363
- 364
- 365
- 366
- 367
- 368
- 369
- 370
- 371
- 372
- 373
- 374
- 375
- 376
- 377
- 378
- 379
- 380
- 381
- 382
- 383
- 384
- 385
- 386
- 387
- 388
- 389
- 390
- 391
- 392
- 393
- 394
- 395
- 396
- 397
- 398
- 399
- 400
- 401
- 402
- 403
- 404
- 405
- 406
- 407
- 408
- 409
- 410
- 411
- 412
- 413
- 414
- 415
- 416
- 417
- 418
- 419
- 420
- 421
- 422
- 423
- 424
- 425
- 426
- 427
- 428
- 429
- 430
- 431
- 432
- 433
- 434
- 435
- 436
- 437
- 438
- 439
- 440
- 441
- 442
- 443
- 444
- 445
- 446
- 447
- 448
- 449
- 450
- 451
- 452
- 453
- 454
- 455
- 456
- 457
- 458
- 459
- 460
- 461
- 462
- 463
- 464
- 465
- 466
- 467
- 468
- 469
- 470
- 471
- 472
- 473
- 474
- 475
- 476
- 477
- 478
- 479
- 480
- 481
- 482
- 483
- 484
- 485
- 486
- 487
- 488
- 489
- 490
- 491
- 492
- 493
- 494
- 495
- 496
- 497
- 498
- 499
- 500